ID   TIE2_HUMAN              Reviewed;        1124 AA.
AC   Q02763; A8K6W0; B4DH20; B4DHD3; D3DRK5; E7EWI2; Q5TCU2; Q8IV34;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   16-DEC-2008, sequence version 2.
DT   12-OCT-2022, entry version 230.
DE   RecName: Full=Angiopoietin-1 receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Endothelial tyrosine kinase;
DE   AltName: Full=Tunica interna endothelial cell kinase;
DE   AltName: Full=Tyrosine kinase with Ig and EGF homology domains-2;
DE   AltName: Full=Tyrosine-protein kinase receptor TEK;
DE   AltName: Full=Tyrosine-protein kinase receptor TIE-2;
DE            Short=hTIE2;
DE   AltName: Full=p140 TEK;
DE   AltName: CD_antigen=CD202b;
DE   Flags: Precursor;
GN   Name=TEK; Synonyms=TIE2, VMCM, VMCM1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, TISSUE
RP   SPECIFICITY, AND VARIANT PRO-346.
RC   TISSUE=Placenta;
RX   PubMed=8382358;
RA   Ziegler S.F., Bird T.A., Schneringer J.A., Schooley K.A., Baum P.R.;
RT   "Molecular cloning and characterization of a novel receptor protein
RT   tyrosine kinase from human placenta.";
RL   Oncogene 8:663-670(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3), AND VARIANT
RP   PRO-346.
RC   TISSUE=Brain, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT PRO-346.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT PRO-346.
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 23-37.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [7]
RP   FUNCTION AS RECEPTOR FOR ANGPT1 AND ANGPT2, INTERACTION WITH ANGPT1 AND
RP   ANGPT2, AND AUTOPHOSPHORYLATION.
RX   PubMed=9204896; DOI=10.1126/science.277.5322.55;
RA   Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J.,
RA   Radziejewski C., Compton D.L., McClain J., Aldrich T.H., Papadopoulos N.,
RA   Daly T.J., Davis S., Sato T.N., Yancopoulos G.D.;
RT   "Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo
RT   angiogenesis.";
RL   Science 277:55-60(1997).
RN   [8]
RP   SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, AND TISSUE SPECIFICITY.
RX   PubMed=11806244; DOI=10.1023/a:1012226627813;
RA   Reusch P., Barleon B., Weindel K., Martiny-Baron G., Godde A.,
RA   Siemeister G., Marme D.;
RT   "Identification of a soluble form of the angiopoietin receptor TIE-2
RT   released from endothelial cells and present in human blood.";
RL   Angiogenesis 4:123-131(2001).
RN   [9]
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND PHOSPHORYLATION AT TYR-860; TYR-992 AND TYR-1108.
RX   PubMed=11513602; DOI=10.1021/bi010959e;
RA   Murray B.W., Padrique E.S., Pinko C., McTigue M.A.;
RT   "Mechanistic effects of autophosphorylation on receptor tyrosine kinase
RT   catalysis: enzymatic characterization of Tie2 and phospho-Tie2.";
RL   Biochemistry 40:10243-10253(2001).
RN   [10]
RP   FUNCTION IN REGULATION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY;
RP   ENDOTHELIAL CELL MIGRATION AND REORGANIZATION OF THE ACTIN CYTOSKELETON.
RX   PubMed=12816861; DOI=10.1182/blood-2003-03-0670;
RA   Cascone I., Audero E., Giraudo E., Napione L., Maniero F., Philips M.R.,
RA   Collard J.G., Serini G., Bussolino F.;
RT   "Tie-2-dependent activation of RhoA and Rac1 participates in endothelial
RT   cell motility triggered by angiopoietin-1.";
RL   Blood 102:2482-2490(2003).
RN   [11]
RP   INTERACTION WITH TNIP2, AUTOPHOSPHORYLATION, CATALYTIC ACTIVITY, AND
RP   MUTAGENESIS OF LYS-855.
RX   PubMed=12609966; DOI=10.1161/01.res.0000063422.38690.dc;
RA   Hughes D.P., Marron M.B., Brindle N.P.;
RT   "The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a
RT   novel nuclear factor-kappaB inhibitor ABIN-2.";
RL   Circ. Res. 92:630-636(2003).
RN   [12]
RP   FUNCTION IN REGULATION OF ANGIOGENESIS; CELL SURVIVAL; CELL MIGRATION AND
RP   ACTIVATION OF AKT1, DOMAIN, AND INTERACTION WITH ANGPT1; ANGPT2 AND ANGPT4.
RX   PubMed=15284220; DOI=10.1096/fj.03-1466com;
RA   Lee H.J., Cho C.H., Hwang S.J., Choi H.H., Kim K.T., Ahn S.Y., Kim J.H.,
RA   Oh J.L., Lee G.M., Koh G.Y.;
RT   "Biological characterization of angiopoietin-3 and angiopoietin-4.";
RL   FASEB J. 18:1200-1208(2004).
RN   [13]
RP   FUNCTION AS ANGPT1 RECEPTOR IN PHOSPHORYLATION OF SHC1 AND PIK3R1;
RP   REGULATION OF CELL MIGRATION AND ANGIOGENESIS, AUTOPHOSPHORYLATION,
RP   MUTAGENESIS OF TYR-1102, PHOSPHORYLATION AT TYR-1102, CATALYTIC ACTIVITY,
RP   AND INTERACTION WITH SHC1.
RX   PubMed=14665640; DOI=10.1074/jbc.m307456200;
RA   Audero E., Cascone I., Maniero F., Napione L., Arese M., Lanfrancone L.,
RA   Bussolino F.;
RT   "Adaptor ShcA protein binds tyrosine kinase Tie2 receptor and regulates
RT   migration and sprouting but not survival of endothelial cells.";
RL   J. Biol. Chem. 279:13224-13233(2004).
RN   [14]
RP   INTERACTION WITH TIE1, SUBCELLULAR LOCATION, FUNCTION AS RECEPTOR FOR
RP   ANGPT1 IN PHOSPHORYLATION OF TIE1, AUTOPHOSPHORYLATION, CATALYTIC ACTIVITY,
RP   AND MUTAGENESIS OF LYS-855.
RX   PubMed=15851516; DOI=10.1083/jcb.200411105;
RA   Saharinen P., Kerkela K., Ekman N., Marron M., Brindle N., Lee G.M.,
RA   Augustin H., Koh G.Y., Alitalo K.;
RT   "Multiple angiopoietin recombinant proteins activate the Tie1 receptor
RT   tyrosine kinase and promote its interaction with Tie2.";
RL   J. Cell Biol. 169:239-243(2005).
RN   [15]
RP   FUNCTION AS ANGPT1 RECEPTOR IN ACTIVATION OF AKT1 OR MAPK1/ERK2 AND
RP   MAPK3/ERK1; REGULATION OF ENDOTHELIAL CELL MIGRATION AND CELL SPREADING,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=18425120; DOI=10.1038/ncb1714;
RA   Fukuhara S., Sako K., Minami T., Noda K., Kim H.Z., Kodama T., Shibuya M.,
RA   Takakura N., Koh G.Y., Mochizuki N.;
RT   "Differential function of Tie2 at cell-cell contacts and cell-substratum
RT   contacts regulated by angiopoietin-1.";
RL   Nat. Cell Biol. 10:513-526(2008).
RN   [16]
RP   FUNCTION AS ANGPT1 RECEPTOR IN ACTIVATION OF AKT1 OR MAPK1/ERK2 AND
RP   MAPK3/ERK1; REGULATION OF ENDOTHELIAL CELL MIGRATION AND REGULATION OF
RP   FOCAL ADHESION ASSEMBLY, INTERACTION WITH TIE1, AUTOPHOSPHORYLATION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=18425119; DOI=10.1038/ncb1715;
RA   Saharinen P., Eklund L., Miettinen J., Wirkkala R., Anisimov A.,
RA   Winderlich M., Nottebaum A., Vestweber D., Deutsch U., Koh G.Y.,
RA   Olsen B.R., Alitalo K.;
RT   "Angiopoietins assemble distinct Tie2 signalling complexes in endothelial
RT   cell-cell and cell-matrix contacts.";
RL   Nat. Cell Biol. 10:527-537(2008).
RN   [17]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPRB.
RX   PubMed=19116766; DOI=10.1007/s10456-008-9126-0;
RA   Yacyshyn O.K., Lai P.F.H., Forse K., Teichert-Kuliszewska K., Jurasz P.,
RA   Stewart D.J.;
RT   "Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in human
RT   endothelial cells.";
RL   Angiogenesis 12:25-33(2009).
RN   [18]
RP   INTERACTION WITH CBL, SUBCELLULAR LOCATION, AND UBIQUITINATION.
RX   PubMed=19689429; DOI=10.1042/bj20091010;
RA   Wehrle C., Van Slyke P., Dumont D.J.;
RT   "Angiopoietin-1-induced ubiquitylation of Tie2 by c-Cbl is required for
RT   internalization and degradation.";
RL   Biochem. J. 423:375-380(2009).
RN   [19]
RP   INTERACTION WITH PTPRB.
RX   PubMed=19451274; DOI=10.1083/jcb.200811159;
RA   Winderlich M., Keller L., Cagna G., Broermann A., Kamenyeva O., Kiefer F.,
RA   Deutsch U., Nottebaum A.F., Vestweber D.;
RT   "VE-PTP controls blood vessel development by balancing Tie-2 activity.";
RL   J. Cell Biol. 185:657-671(2009).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-596.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [21]
RP   FUNCTION AS RECEPTOR FOR ANGPT1 AND ANGPT2 IN ACTIVATION OF
RP   PHOSPHATIDYLINOSITOL 3-KINASE AND AKT1; STIMULATION OF ENDOTHELIAL CELL
RP   SURVIVAL AND MIGRATION, CATALYTIC ACTIVITY, AND AUTOPHOSPHORYLATION.
RX   PubMed=19223473; DOI=10.1128/mcb.01472-08;
RA   Yuan H.T., Khankin E.V., Karumanchi S.A., Parikh S.M.;
RT   "Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the
RT   endothelium.";
RL   Mol. Cell. Biol. 29:2011-2022(2009).
RN   [22]
RP   REVIEW ON FUNCTION; INTERACTION WITH EFFECTOR AND SCAFFOLDING PROTEINS, AND
RP   ROLE IN DISEASE.
RX   PubMed=18366015; DOI=10.14670/hh-23.773;
RA   Martin V., Liu D., Fueyo J., Gomez-Manzano C.;
RT   "Tie2: a journey from normal angiogenesis to cancer and beyond.";
RL   Histol. Histopathol. 23:773-780(2008).
RN   [23]
RP   REVIEW ON SUBCELLULAR LOCATION AND CONTEXT-SPECIFIC SIGNALING.
RX   PubMed=19293632; DOI=10.3858/emm.2009.41.3.016;
RA   Fukuhara S., Sako K., Noda K., Nagao K., Miura K., Mochizuki N.;
RT   "Tie2 is tied at the cell-cell contacts and to extracellular matrix by
RT   angiopoietin-1.";
RL   Exp. Mol. Med. 41:133-139(2009).
RN   [24]
RP   REVIEW.
RX   PubMed=19234476; DOI=10.1038/nrm2639;
RA   Augustin H.G., Koh G.Y., Thurston G., Alitalo K.;
RT   "Control of vascular morphogenesis and homeostasis through the
RT   angiopoietin-Tie system.";
RL   Nat. Rev. Mol. Cell Biol. 10:165-177(2009).
RN   [25]
RP   REVIEW.
RX   PubMed=20054809; DOI=10.14670/hh-25.387;
RA   Fukuhara S., Sako K., Noda K., Zhang J., Minami M., Mochizuki N.;
RT   "Angiopoietin-1/Tie2 receptor signaling in vascular quiescence and
RT   angiogenesis.";
RL   Histol. Histopathol. 25:387-396(2010).
RN   [26]
RP   REVIEW ON SIGNALING, ACTIVITY REGULATION, AND ROLE IN DISEASE.
RX   PubMed=20651738; DOI=10.1038/nrc2894;
RA   Huang H., Bhat A., Woodnutt G., Lappe R.;
RT   "Targeting the ANGPT-TIE2 pathway in malignancy.";
RL   Nat. Rev. Cancer 10:575-585(2010).
RN   [27]
RP   INTERACTION WITH ANGPT2.
RX   PubMed=32908006; DOI=10.1126/scitranslmed.aax8013;
RA   Leppaenen V.M., Brouillard P., Korhonen E.A., Sipilae T., Jha S.K.,
RA   Revencu N., Labarque V., Fastre E., Schloegel M., Ravoet M., Singer A.,
RA   Luzzatto C., Angelone D., Crichiutti G., D'Elia A., Kuurne J., Elamaa H.,
RA   Koh G.Y., Saharinen P., Vikkula M., Alitalo K.;
RT   "Characterization of ANGPT2 mutations associated with primary lymphedema.";
RL   Sci. Transl. Med. 12:0-0(2020).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 808-1124, ACTIVE SITE, ACTIVITY
RP   REGULATION, AND PREDICTION OF ATP-BINDING REGION.
RX   PubMed=11080633; DOI=10.1016/s0969-2126(00)00516-5;
RA   Shewchuk L.M., Hassell A.M., Ellis B., Holmes W.D., Davis R., Horne E.L.,
RA   Kadwell S.H., McKee D.D., Moore J.T.;
RT   "Structure of the Tie2 RTK domain: self-inhibition by the nucleotide
RT   binding loop, activation loop, and C-terminal tail.";
RL   Structure 8:1105-1113(2000).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-445 ALONE AND IN COMPLEX WITH
RP   ANGPT2, GLYCOSYLATION AT ASN-140, AND DISULFIDE BONDS.
RX   PubMed=16732286; DOI=10.1038/nsmb1101;
RA   Barton W.A., Tzvetkova-Robev D., Miranda E.P., Kolev M.V.,
RA   Rajashankar K.R., Himanen J.P., Nikolov D.B.;
RT   "Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2-
RT   Tie2 complex.";
RL   Nat. Struct. Mol. Biol. 13:524-532(2006).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 808-1124 IN COMPLEX WITH TRIAZINE
RP   DERIVATIVE, AND ACTIVITY REGULATION.
RX   PubMed=17350837; DOI=10.1016/j.bmcl.2007.02.067;
RA   Hodous B.L., Geuns-Meyer S.D., Hughes P.E., Albrecht B.K., Bellon S.,
RA   Caenepeel S., Cee V.J., Chaffee S.C., Emery M., Fretland J., Gallant P.,
RA   Gu Y., Johnson R.E., Kim J.L., Long A.M., Morrison M., Olivieri P.R.,
RA   Patel V.F., Polverino A., Rose P., Wang L., Zhao H.;
RT   "Synthesis, structural analysis, and SAR studies of triazine derivatives as
RT   potent, selective Tie-2 inhibitors.";
RL   Bioorg. Med. Chem. Lett. 17:2886-2889(2007).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 808-1124 IN COMPLEX WITH TRIAZINE
RP   DERIVATIVE, AND ACTIVITY REGULATION.
RX   PubMed=17253678; DOI=10.1021/jm061107l;
RA   Hodous B.L., Geuns-Meyer S.D., Hughes P.E., Albrecht B.K., Bellon S.,
RA   Bready J., Caenepeel S., Cee V.J., Chaffee S.C., Coxon A., Emery M.,
RA   Fretland J., Gallant P., Gu Y., Hoffman D., Johnson R.E., Kendall R.,
RA   Kim J.L., Long A.M., Morrison M., Olivieri P.R., Patel V.F., Polverino A.,
RA   Rose P., Tempest P., Wang L., Whittington D.A., Zhao H.;
RT   "Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine
RT   Tie-2 kinase inhibitor.";
RL   J. Med. Chem. 50:611-626(2007).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.95 ANGSTROMS) OF 802-1124 IN COMPLEX WITH
RP   THIAZOLOPYRIMIDINE DERIVATIVE, AND ACTIVITY REGULATION.
RX   PubMed=19854647; DOI=10.1016/j.bmcl.2009.10.001;
RA   Luke R.W., Ballard P., Buttar D., Campbell L., Curwen J., Emery S.C.,
RA   Griffen A.M., Hassall L., Hayter B.R., Jones C.D., McCoull W., Mellor M.,
RA   Swain M.L., Tucker J.A.;
RT   "Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with
RT   activity against Tie-2 in vitro and in vivo.";
RL   Bioorg. Med. Chem. Lett. 19:6670-6674(2009).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 808-1124 IN COMPLEX WITH
RP   CEP11207.
RA   Fedorov A.A., Fedorov E.V., Pauletti D., Meyer S.L., Hudkins R.L.,
RA   Almo S.C.;
RT   "Crystal structure of cytoplasmic kinase domain of Tie2 complexed with
RT   inhibitor CEP11207.";
RL   Submitted (JAN-2010) to the PDB data bank.
RN   [34]
RP   VARIANT VMCM TRP-849.
RX   PubMed=8980225; DOI=10.1016/s0092-8674(00)81814-0;
RA   Vikkula M., Boon L.M., Carraway K.L. III, Calvert J.T., Diamonti A.J.,
RA   Goumnerov B., Pasyk K.A., Marchuk D.A., Warman M.L., Cantley L.C.,
RA   Mulliken J.B., Olse B.R.;
RT   "Vascular dysmorphogenesis caused by an activating mutation in the receptor
RT   tyrosine kinase TIE2.";
RL   Cell 87:1181-1190(1996).
RN   [35]
RP   VARIANTS VMCM TRP-849 AND SER-897.
RX   PubMed=10369874; DOI=10.1093/hmg/8.7.1279;
RA   Calvert J.T., Riney T.J., Kontos C.D., Cha E.H., Prieto V.G., Shea C.R.,
RA   Berg J.N., Nevin N.C., Simpson S.A., Pasyk K.A., Speer M.C., Peters K.G.,
RA   Marchuk D.A.;
RT   "Allelic and locus heterogeneity in inherited venous malformations.";
RL   Hum. Mol. Genet. 8:1279-1289(1999).
RN   [36]
RP   VARIANT [LARGE SCALE ANALYSIS] ASN-117.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [37]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-117; THR-148; VAL-226; ILE-486;
RP   LEU-600; PHE-634; ILE-676; THR-724; ALA-883 AND VAL-1124.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [38]
RP   INVOLVEMENT IN VMCM, INVOLVEMENT IN DISEASE, SUBCELLULAR LOCATION,
RP   CHARACTERIZATION OF VARIANTS VMCM TRP-849, VARIANTS HIS-897; PHE-897;
RP   SER-897; PHE-914; CYS-915; LEU-915 AND ILE-917, CHARACTERIZATION OF
RP   VARIANTS HIS-897; PHE-897; SER-897; PHE-914; CYS-915; LEU-915 AND ILE-917,
RP   AND PHOSPHORYLATION AT TYR-1102.
RX   PubMed=19079259; DOI=10.1038/ng.272;
RA   Limaye N., Wouters V., Uebelhoer M., Tuominen M., Wirkkala R.,
RA   Mulliken J.B., Eklund L., Boon L.M., Vikkula M.;
RT   "Somatic mutations in angiopoietin receptor gene TEK cause solitary and
RT   multiple sporadic venous malformations.";
RL   Nat. Genet. 41:118-124(2009).
RN   [39]
RP   VARIANTS VMCM TRP-849; CYS-897; HIS-915; CYS-918; LEU-919; SER-925 AND
RP   ASN-1100, AND CHARACTERIZATION OF VARIANTS VMCM TRP-849; SER-897; HIS-915;
RP   CYS-918; LEU-919; SER-925 AND ASN-1100.
RX   PubMed=19888299; DOI=10.1038/ejhg.2009.193;
RA   Wouters V., Limaye N., Uebelhoer M., Irrthum A., Boon L.M., Mulliken J.B.,
RA   Enjolras O., Baselga E., Berg J., Dompmartin A., Ivarsson S.A., Kangesu L.,
RA   Lacassie Y., Murphy J., Teebi A.S., Penington A., Rieu P., Vikkula M.;
RT   "Hereditary cutaneomucosal venous malformations are caused by TIE2
RT   mutations with widely variable hyper-phosphorylating effects.";
RL   Eur. J. Hum. Genet. 18:414-420(2010).
RN   [40]
RP   INVOLVEMENT IN GLC3E, VARIANTS GLC3E 19-THR--ARG-210 DEL; TYR-233; ASN-294
RP   AND CYS-611, CHARACTERIZATION OF VARIANTS GLC3E 19-THR--ARG-210 DEL;
RP   TYR-233; ASN-294 AND CYS-611, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   CYS-224.
RX   PubMed=27270174; DOI=10.1172/jci85830;
RA   Souma T., Tompson S.W., Thomson B.R., Siggs O.M., Kizhatil K.,
RA   Yamaguchi S., Feng L., Limviphuvadh V., Whisenhunt K.N., Maurer-Stroh S.,
RA   Yanovitch T.L., Kalaydjieva L., Azmanov D.N., Finzi S., Mauri L.,
RA   Javadiyan S., Souzeau E., Zhou T., Hewitt A.W., Kloss B., Burdon K.P.,
RA   Mackey D.A., Allen K.F., Ruddle J.B., Lim S.H., Rozen S., Tran-Viet K.N.,
RA   Liu X., John S., Wiggs J.L., Pasutto F., Craig J.E., Jin J., Quaggin S.E.,
RA   Young T.L.;
RT   "Angiopoietin receptor TEK mutations underlie primary congenital glaucoma
RT   with variable expressivity.";
RL   J. Clin. Invest. 126:2575-2587(2016).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor
CC       for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial
CC       cell survival, proliferation, migration, adhesion and cell spreading,
CC       reorganization of the actin cytoskeleton, but also maintenance of
CC       vascular quiescence. Has anti-inflammatory effects by preventing the
CC       leakage of pro-inflammatory plasma proteins and leukocytes from blood
CC       vessels. Required for normal angiogenesis and heart development during
CC       embryogenesis. Required for post-natal hematopoiesis. After birth,
CC       activates or inhibits angiogenesis, depending on the context. Inhibits
CC       angiogenesis and promotes vascular stability in quiescent vessels,
CC       where endothelial cells have tight contacts. In quiescent vessels,
CC       ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes
CC       with TEK molecules from adjoining cells, and this leads to preferential
CC       activation of phosphatidylinositol 3-kinase and the AKT1 signaling
CC       cascades. In migrating endothelial cells that lack cell-cell adhesions,
CC       ANGT1 recruits TEK to contacts with the extracellular matrix, leading
CC       to the formation of focal adhesion complexes, activation of PTK2/FAK
CC       and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately
CC       to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers
CC       receptor dimerization and autophosphorylation at specific tyrosine
CC       residues that then serve as binding sites for scaffold proteins and
CC       effectors. Signaling is modulated by ANGPT2 that has lower affinity for
CC       TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but
CC       inhibits ANGPT1-mediated signaling by competing for the same binding
CC       site. Signaling is also modulated by formation of heterodimers with
CC       TIE1, and by proteolytic processing that gives rise to a soluble TEK
CC       extracellular domain. The soluble extracellular domain modulates
CC       signaling by functioning as decoy receptor for angiopoietins. TEK
CC       phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1.
CC       {ECO:0000269|PubMed:12816861, ECO:0000269|PubMed:14665640,
CC       ECO:0000269|PubMed:15284220, ECO:0000269|PubMed:15851516,
CC       ECO:0000269|PubMed:18366015, ECO:0000269|PubMed:18425119,
CC       ECO:0000269|PubMed:18425120, ECO:0000269|PubMed:19223473,
CC       ECO:0000269|PubMed:20651738, ECO:0000269|PubMed:9204896}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:11513602, ECO:0000269|PubMed:12609966,
CC         ECO:0000269|PubMed:14665640, ECO:0000269|PubMed:15851516,
CC         ECO:0000269|PubMed:19223473, ECO:0000269|PubMed:8382358};
CC   -!- ACTIVITY REGULATION: Angiopoietin binding leads to receptor
CC       dimerization and activation by autophosphorylation at Tyr-992 on the
CC       kinase activation loop. Inhibited by staurosporine, K252a, PP2,
CC       damnacanthal, SB203580, CEP-11207, CEP-11981 and CE-245677. Inhibited
CC       by triazine, thienopyrimidine and thiazolopyrimidine derivatives.
CC       {ECO:0000269|PubMed:11080633, ECO:0000269|PubMed:11513602,
CC       ECO:0000269|PubMed:17253678, ECO:0000269|PubMed:17350837,
CC       ECO:0000269|PubMed:19854647, ECO:0000269|PubMed:20651738}.
CC   -!- SUBUNIT: Homodimer. Heterodimer with TIE1. Interacts with ANGPT1,
CC       ANGPT2 and ANGPT4 (PubMed:9204896, PubMed:15284220, PubMed:32908006).
CC       At cell-cell contacts in quiescent cells, forms a signaling complex
CC       composed of ANGPT1 plus TEK molecules from two adjoining cells. In the
CC       absence of endothelial cell-cell contacts, interaction with ANGPT1
CC       mediates contacts with the extracellular matrix. Interacts with PTPRB;
CC       this promotes endothelial cell-cell adhesion. Interacts with DOK2,
CC       GRB2, GRB7, GRB14, PIK3R1 and PTPN11/SHP2. Colocalizes with DOK2 at
CC       contacts with the extracellular matrix in migrating cells. Interacts
CC       (tyrosine phosphorylated) with TNIP2. Interacts (tyrosine
CC       phosphorylated) with SHC1 (via SH2 domain).
CC       {ECO:0000269|PubMed:12609966, ECO:0000269|PubMed:14665640,
CC       ECO:0000269|PubMed:15284220, ECO:0000269|PubMed:15851516,
CC       ECO:0000269|PubMed:16732286, ECO:0000269|PubMed:17253678,
CC       ECO:0000269|PubMed:17350837, ECO:0000269|PubMed:18425119,
CC       ECO:0000269|PubMed:19451274, ECO:0000269|PubMed:19689429,
CC       ECO:0000269|PubMed:19854647, ECO:0000269|PubMed:32908006,
CC       ECO:0000269|PubMed:9204896, ECO:0000269|Ref.33}.
CC   -!- INTERACTION:
CC       Q02763; Q15389: ANGPT1; NbExp=2; IntAct=EBI-2257090, EBI-2922365;
CC       Q02763; O15123: ANGPT2; NbExp=4; IntAct=EBI-2257090, EBI-2912111;
CC       Q02763; O15123-1: ANGPT2; NbExp=5; IntAct=EBI-2257090, EBI-15552475;
CC       Q02763; Q16678: CYP1B1; NbExp=6; IntAct=EBI-2257090, EBI-1055133;
CC       Q02763; Q05209: PTPN12; NbExp=2; IntAct=EBI-2257090, EBI-2266035;
CC       Q02763; P23467: PTPRB; NbExp=3; IntAct=EBI-2257090, EBI-1265766;
CC       Q02763; P08575: PTPRC; NbExp=3; IntAct=EBI-2257090, EBI-1341;
CC       Q02763; Q12913: PTPRJ; NbExp=2; IntAct=EBI-2257090, EBI-2264500;
CC       Q02763; Q15262: PTPRK; NbExp=2; IntAct=EBI-2257090, EBI-474052;
CC       Q02763; Q16827: PTPRO; NbExp=2; IntAct=EBI-2257090, EBI-723739;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18425119,
CC       ECO:0000269|PubMed:18425120, ECO:0000269|PubMed:19079259,
CC       ECO:0000269|PubMed:27270174}; Single-pass type I membrane protein. Cell
CC       junction {ECO:0000269|PubMed:18425119, ECO:0000269|PubMed:18425120,
CC       ECO:0000269|PubMed:27270174}. Cell junction, focal adhesion
CC       {ECO:0000305|PubMed:19293632}. Cytoplasm, cytoskeleton. Secreted
CC       {ECO:0000269|PubMed:11806244}. Note=Recruited to cell-cell contacts in
CC       quiescent endothelial cells (PubMed:18425120, PubMed:18425119).
CC       Colocalizes with the actin cytoskeleton and at actin stress fibers
CC       during cell spreading. Recruited to the lower surface of migrating
CC       cells, especially the rear end of the cell. Proteolytic processing
CC       gives rise to a soluble extracellular domain that is secreted
CC       (PubMed:11806244). {ECO:0000269|PubMed:11806244,
CC       ECO:0000269|PubMed:18425119, ECO:0000269|PubMed:18425120}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q02763-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q02763-2; Sequence=VSP_042138;
CC       Name=3;
CC         IsoId=Q02763-3; Sequence=VSP_042137, VSP_042138, VSP_042139;
CC   -!- TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells.
CC       Proteolytic processing gives rise to a soluble extracellular domain
CC       that is detected in blood plasma (at protein level). Predominantly
CC       expressed in endothelial cells and their progenitors, the angioblasts.
CC       Has been directly found in placenta and lung, with a lower level in
CC       umbilical vein endothelial cells, brain and kidney.
CC       {ECO:0000269|PubMed:11806244, ECO:0000269|PubMed:8382358}.
CC   -!- DOMAIN: The soluble extracellular domain is functionally active in
CC       angiopoietin binding and can modulate the activity of the membrane-
CC       bound form by competing for angiopoietins.
CC       {ECO:0000269|PubMed:15284220}.
CC   -!- PTM: Proteolytic processing leads to the shedding of the extracellular
CC       domain (soluble TIE-2 alias sTIE-2). {ECO:0000269|PubMed:11806244}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to ligand
CC       binding. Autophosphorylation occurs in trans, i.e. one subunit of the
CC       dimeric receptor phosphorylates tyrosine residues on the other subunit.
CC       Autophosphorylation occurs in a sequential manner, where Tyr-992 in the
CC       kinase activation loop is phosphorylated first, followed by
CC       autophosphorylation at Tyr-1108 and at additional tyrosine residues.
CC       ANGPT1-induced phosphorylation is impaired during hypoxia, due to
CC       increased expression of ANGPT2. Phosphorylation is important for
CC       interaction with GRB14, PIK3R1 and PTPN11. Phosphorylation at Tyr-1102
CC       is important for interaction with SHC1, GRB2 and GRB7. Phosphorylation
CC       at Tyr-1108 is important for interaction with DOK2 and for coupling to
CC       downstream signal transduction pathways in endothelial cells.
CC       Dephosphorylated by PTPRB. {ECO:0000269|PubMed:11513602,
CC       ECO:0000269|PubMed:14665640}.
CC   -!- PTM: Ubiquitinated. The phosphorylated receptor is ubiquitinated and
CC       internalized, leading to its degradation.
CC       {ECO:0000269|PubMed:19689429}.
CC   -!- DISEASE: Dominantly inherited venous malformations (VMCM) [MIM:600195]:
CC       An error of vascular morphogenesis characterized by dilated,
CC       serpiginous channels. {ECO:0000269|PubMed:10369874,
CC       ECO:0000269|PubMed:19079259, ECO:0000269|PubMed:19888299,
CC       ECO:0000269|PubMed:8980225}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Somatic mutations of TEK are associated with solitary and
CC       multiple sporadic venous malformations. {ECO:0000269|PubMed:19079259}.
CC   -!- DISEASE: Note=May play a role in a range of diseases with a vascular
CC       component, including neovascularization of tumors, psoriasis and
CC       inflammation.
CC   -!- DISEASE: Glaucoma 3, primary congenital, E (GLC3E) [MIM:617272]: An
CC       autosomal dominant form of primary congenital glaucoma (PCG). PCG is
CC       characterized by marked increase of intraocular pressure at birth or
CC       early childhood, large ocular globes (buphthalmos) and corneal edema.
CC       It results from developmental defects of the trabecular meshwork and
CC       anterior chamber angle of the eye that prevent adequate drainage of
CC       aqueous humor. {ECO:0000269|PubMed:27270174}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Tie subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TEKID42517ch9p21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L06139; AAA61139.1; -; mRNA.
DR   EMBL; AK291775; BAF84464.1; -; mRNA.
DR   EMBL; AK294887; BAG57981.1; -; mRNA.
DR   EMBL; AK295043; BAG58094.1; -; mRNA.
DR   EMBL; AL133411; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL355432; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL355433; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471071; EAW58571.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58572.1; -; Genomic_DNA.
DR   EMBL; BC035514; AAH35514.2; -; mRNA.
DR   CCDS; CCDS6519.1; -. [Q02763-1]
DR   CCDS; CCDS75825.1; -. [Q02763-2]
DR   CCDS; CCDS78389.1; -. [Q02763-3]
DR   PIR; I58388; I58388.
DR   RefSeq; NP_000450.2; NM_000459.4. [Q02763-1]
DR   RefSeq; NP_001277006.1; NM_001290077.1.
DR   RefSeq; NP_001277007.1; NM_001290078.1.
DR   PDB; 1FVR; X-ray; 2.20 A; A/B=808-1124.
DR   PDB; 2GY5; X-ray; 2.90 A; A=23-445.
DR   PDB; 2GY7; X-ray; 3.70 A; B=23-445.
DR   PDB; 2OO8; X-ray; 2.20 A; X=808-1124.
DR   PDB; 2OSC; X-ray; 2.80 A; A=808-1124.
DR   PDB; 2P4I; X-ray; 2.50 A; A/B=808-1124.
DR   PDB; 2WQB; X-ray; 2.95 A; A=802-1124.
DR   PDB; 3BEA; X-ray; 2.02 A; A=917-935.
DR   PDB; 3L8P; X-ray; 2.40 A; A=808-1124.
DR   PDB; 4K0V; X-ray; 4.51 A; A=23-542.
DR   PDB; 4X3J; X-ray; 2.50 A; A=802-1122.
DR   PDB; 5MYA; X-ray; 2.90 A; A/B=443-742.
DR   PDB; 5MYB; X-ray; 2.60 A; A/B=443-742.
DR   PDB; 5UTK; X-ray; 2.50 A; A/B=442-741.
DR   PDB; 6MWE; X-ray; 2.05 A; A/B=808-1124.
DR   PDB; 7E72; X-ray; 2.09 A; E/F=541-735.
DR   PDBsum; 1FVR; -.
DR   PDBsum; 2GY5; -.
DR   PDBsum; 2GY7; -.
DR   PDBsum; 2OO8; -.
DR   PDBsum; 2OSC; -.
DR   PDBsum; 2P4I; -.
DR   PDBsum; 2WQB; -.
DR   PDBsum; 3BEA; -.
DR   PDBsum; 3L8P; -.
DR   PDBsum; 4K0V; -.
DR   PDBsum; 4X3J; -.
DR   PDBsum; 5MYA; -.
DR   PDBsum; 5MYB; -.
DR   PDBsum; 5UTK; -.
DR   PDBsum; 6MWE; -.
DR   PDBsum; 7E72; -.
DR   AlphaFoldDB; Q02763; -.
DR   SMR; Q02763; -.
DR   BioGRID; 112869; 25.
DR   DIP; DIP-6047N; -.
DR   IntAct; Q02763; 112.
DR   MINT; Q02763; -.
DR   STRING; 9606.ENSP00000369375; -.
DR   BindingDB; Q02763; -.
DR   ChEMBL; CHEMBL4128; -.
DR   DrugBank; DB00415; Ampicillin.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB08221; N-{4-METHYL-3-[(3-PYRIMIDIN-4-YLPYRIDIN-2-YL)AMINO]PHENYL}-3-(TRIFLUOROMETHYL)BENZAMIDE.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB14840; Ripretinib.
DR   DrugBank; DB11800; Tivozanib.
DR   DrugBank; DB05294; Vandetanib.
DR   DrugCentral; Q02763; -.
DR   GuidetoPHARMACOLOGY; 1842; -.
DR   GlyConnect; 769; 10 N-Linked glycans (5 sites).
DR   GlyGen; Q02763; 10 sites, 1 Asn glycan (1 site), 10 N-linked glycans (5 sites).
DR   iPTMnet; Q02763; -.
DR   PhosphoSitePlus; Q02763; -.
DR   BioMuta; TEK; -.
DR   DMDM; 218511853; -.
DR   EPD; Q02763; -.
DR   MassIVE; Q02763; -.
DR   PaxDb; Q02763; -.
DR   PeptideAtlas; Q02763; -.
DR   PRIDE; Q02763; -.
DR   ProteomicsDB; 58121; -. [Q02763-1]
DR   ProteomicsDB; 58122; -. [Q02763-2]
DR   ProteomicsDB; 58123; -. [Q02763-3]
DR   ABCD; Q02763; 9 sequenced antibodies.
DR   Antibodypedia; 2050; 1424 antibodies from 43 providers.
DR   DNASU; 7010; -.
DR   Ensembl; ENST00000380036.10; ENSP00000369375.4; ENSG00000120156.22. [Q02763-1]
DR   Ensembl; ENST00000406359.8; ENSP00000383977.4; ENSG00000120156.22. [Q02763-2]
DR   Ensembl; ENST00000519097.5; ENSP00000430686.1; ENSG00000120156.22. [Q02763-3]
DR   GeneID; 7010; -.
DR   KEGG; hsa:7010; -.
DR   MANE-Select; ENST00000380036.10; ENSP00000369375.4; NM_000459.5; NP_000450.3.
DR   UCSC; uc003zqi.5; human. [Q02763-1]
DR   CTD; 7010; -.
DR   DisGeNET; 7010; -.
DR   GeneCards; TEK; -.
DR   GeneReviews; TEK; -.
DR   HGNC; HGNC:11724; TEK.
DR   HPA; ENSG00000120156; Tissue enhanced (placenta).
DR   MalaCards; TEK; -.
DR   MIM; 600195; phenotype.
DR   MIM; 600221; gene.
DR   MIM; 617272; phenotype.
DR   neXtProt; NX_Q02763; -.
DR   OpenTargets; ENSG00000120156; -.
DR   Orphanet; 1059; Blue rubber bleb nevus.
DR   Orphanet; 98976; Congenital glaucoma.
DR   Orphanet; 2451; Mucocutaneous venous malformations.
DR   PharmGKB; PA36441; -.
DR   VEuPathDB; HostDB:ENSG00000120156; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   GeneTree; ENSGT00940000158840; -.
DR   HOGENOM; CLU_008888_0_0_1; -.
DR   InParanoid; Q02763; -.
DR   OMA; PEGITLF; -.
DR   OrthoDB; 707342at2759; -.
DR   PhylomeDB; Q02763; -.
DR   TreeFam; TF317568; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; Q02763; -.
DR   Reactome; R-HSA-210993; Tie2 Signaling.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; Q02763; -.
DR   SIGNOR; Q02763; -.
DR   BioGRID-ORCS; 7010; 3 hits in 1105 CRISPR screens.
DR   ChiTaRS; TEK; human.
DR   EvolutionaryTrace; Q02763; -.
DR   GeneWiki; TEK_tyrosine_kinase; -.
DR   GenomeRNAi; 7010; -.
DR   Pharos; Q02763; Tclin.
DR   PRO; PR:Q02763; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; Q02763; protein.
DR   Bgee; ENSG00000120156; Expressed in right lung and 154 other tissues.
DR   ExpressionAtlas; Q02763; baseline and differential.
DR   Genevisible; Q02763; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0009925; C:basal plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0034451; C:centriolar satellite; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-KW.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005925; C:focal adhesion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005902; C:microvillus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0001525; P:angiogenesis; ISS:UniProtKB.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0060216; P:definitive hemopoiesis; TAS:UniProtKB.
DR   GO; GO:0001935; P:endothelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0072012; P:glomerulus vasculature development; ISS:UniProtKB.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0060347; P:heart trabecula formation; ISS:UniProtKB.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; ISS:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; TAS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000251; P:positive regulation of actin cytoskeleton reorganization; IMP:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IDA:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; TAS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; IMP:UniProtKB.
DR   GO; GO:1902533; P:positive regulation of intracellular signal transduction; IMP:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IMP:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IMP:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:2000351; P:regulation of endothelial cell apoptotic process; TAS:UniProtKB.
DR   GO; GO:0032878; P:regulation of establishment or maintenance of cell polarity; IMP:UniProtKB.
DR   GO; GO:0043114; P:regulation of vascular permeability; TAS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0002040; P:sprouting angiogenesis; IMP:UniProtKB.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IMP:UniProtKB.
DR   GO; GO:0048014; P:Tie signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IDA:UniProtKB.
DR   CDD; cd00055; EGF_Lam; 2.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.40.10; -; 6.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR002049; LE_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR018941; Tyr_kin_Tie2_Ig-like_dom-1_N.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF00041; fn3; 3.
DR   Pfam; PF10430; Ig_Tie2_1; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00181; EGF; 3.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF49265; SSF49265; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00022; EGF_1; 3.
DR   PROSITE; PS01186; EGF_2; 3.
DR   PROSITE; PS50026; EGF_3; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; ATP-binding;
KW   Cell junction; Cell membrane; Cytoplasm; Cytoskeleton;
KW   Direct protein sequencing; Disease variant; Disulfide bond;
KW   EGF-like domain; Glaucoma; Glycoprotein; Immunoglobulin domain; Kinase;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Receptor; Reference proteome;
KW   Repeat; Secreted; Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL          1..22
FT                   /evidence="ECO:0000269|PubMed:15340161"
FT   CHAIN           23..1124
FT                   /note="Angiopoietin-1 receptor"
FT                   /id="PRO_0000024474"
FT   TOPO_DOM        23..748
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        749..769
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        770..1124
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          44..123
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          210..252
FT                   /note="EGF-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          254..299
FT                   /note="EGF-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          301..341
FT                   /note="EGF-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          350..440
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          447..541
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          545..636
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          641..735
FT                   /note="Fibronectin type-III 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          824..1096
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ACT_SITE        964
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000305|PubMed:11080633"
FT   BINDING         830..838
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   BINDING         855
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         860
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11513602"
FT   MOD_RES         992
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11513602"
FT   MOD_RES         1102
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:14665640,
FT                   ECO:0000269|PubMed:27270174"
FT   MOD_RES         1108
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11513602"
FT   CARBOHYD        140
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16732286"
FT   CARBOHYD        158
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        399
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        438
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        464
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        560
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        596
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        649
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        691
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        44..102
FT                   /evidence="ECO:0000269|PubMed:16732286"
FT   DISULFID        211..220
FT                   /evidence="ECO:0000269|PubMed:16732286"
FT   DISULFID        224..233
FT                   /evidence="ECO:0000269|PubMed:16732286"
FT   DISULFID        227..240
FT                   /evidence="ECO:0000269|PubMed:16732286"
FT   DISULFID        242..251
FT                   /evidence="ECO:0000269|PubMed:16732286"
FT   DISULFID        255..264
FT                   /evidence="ECO:0000269|PubMed:16732286"
FT   DISULFID        268..274
FT                   /evidence="ECO:0000269|PubMed:16732286"
FT   DISULFID        280..287
FT                   /evidence="ECO:0000269|PubMed:16732286"
FT   DISULFID        289..298
FT                   /evidence="ECO:0000269|PubMed:16732286"
FT   DISULFID        302..311
FT                   /evidence="ECO:0000269|PubMed:16732286"
FT   DISULFID        315..323
FT                   /evidence="ECO:0000269|PubMed:16732286"
FT   DISULFID        317..329
FT                   /evidence="ECO:0000269|PubMed:16732286"
FT   DISULFID        331..340
FT                   /evidence="ECO:0000269|PubMed:16732286"
FT   DISULFID        370..424
FT                   /evidence="ECO:0000269|PubMed:16732286"
FT   VAR_SEQ         18..121
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042137"
FT   VAR_SEQ         300..342
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042138"
FT   VAR_SEQ         788
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042139"
FT   VARIANT         19..210
FT                   /note="Missing (in GLC3E; formation of protein aggregates)"
FT                   /evidence="ECO:0000269|PubMed:27270174"
FT                   /id="VAR_078045"
FT   VARIANT         117
FT                   /note="K -> N (in breast cancer samples; infiltrating
FT                   ductal carcinoma; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_035714"
FT   VARIANT         148
FT                   /note="I -> T (in dbSNP:rs35969327)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041855"
FT   VARIANT         226
FT                   /note="A -> V (in dbSNP:rs35814893)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041856"
FT   VARIANT         233
FT                   /note="C -> Y (in GLC3E; enhanced proteasomal degradation)"
FT                   /evidence="ECO:0000269|PubMed:27270174"
FT                   /id="VAR_078046"
FT   VARIANT         294
FT                   /note="K -> N (in GLC3E; unknown pathological significance;
FT                   10-fold decrease of Tyr-1102 phosphorylation; no effect on
FT                   membrane location; dbSNP:rs146169480)"
FT                   /evidence="ECO:0000269|PubMed:27270174"
FT                   /id="VAR_078047"
FT   VARIANT         346
FT                   /note="Q -> P (in dbSNP:rs682632)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:8382358,
FT                   ECO:0000269|Ref.4"
FT                   /id="VAR_048002"
FT   VARIANT         391
FT                   /note="T -> I (in dbSNP:rs34032300)"
FT                   /id="VAR_048003"
FT   VARIANT         486
FT                   /note="V -> I (in dbSNP:rs1334811)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_024578"
FT   VARIANT         600
FT                   /note="V -> L (in dbSNP:rs35030851)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041857"
FT   VARIANT         611
FT                   /note="Y -> C (in GLC3E; reduced response to ligand; loss
FT                   of ligand-induced phosphorylation; no effect on basal
FT                   membrane location; dbSNP:rs1306527531)"
FT                   /evidence="ECO:0000269|PubMed:27270174"
FT                   /id="VAR_078048"
FT   VARIANT         634
FT                   /note="L -> F (in dbSNP:rs35378598)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041858"
FT   VARIANT         676
FT                   /note="V -> I (in dbSNP:rs56367117)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041859"
FT   VARIANT         724
FT                   /note="A -> T (in dbSNP:rs4631561)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041860"
FT   VARIANT         849
FT                   /note="R -> W (in VMCM; increased ligand-independent
FT                   autophosphorylation and kinase activation; no effect on
FT                   location at membrane; dbSNP:rs80338908)"
FT                   /evidence="ECO:0000269|PubMed:10369874,
FT                   ECO:0000269|PubMed:19079259, ECO:0000269|PubMed:19888299,
FT                   ECO:0000269|PubMed:8980225"
FT                   /id="VAR_006352"
FT   VARIANT         883
FT                   /note="P -> A (in an ovarian serous carcinoma sample;
FT                   somatic mutation; dbSNP:rs1490428165)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041861"
FT   VARIANT         897
FT                   /note="Y -> C (in VMCM; increased ligand-independent
FT                   autophosphorylation and kinase activation;
FT                   dbSNP:rs80338909)"
FT                   /evidence="ECO:0000269|PubMed:19888299"
FT                   /id="VAR_066606"
FT   VARIANT         897
FT                   /note="Y -> F (found in a patient with multiple sporadic
FT                   venous malformations; increased ligand-independent
FT                   autophosphorylation; the hyperphosphorylation increases
FT                   when associated with Leu-915)"
FT                   /evidence="ECO:0000269|PubMed:19079259"
FT                   /id="VAR_078049"
FT   VARIANT         897
FT                   /note="Y -> H (found in a patient with solitary sporadic
FT                   venous malformations; increased ligand-independent
FT                   autophosphorylation)"
FT                   /evidence="ECO:0000269|PubMed:19079259"
FT                   /id="VAR_078050"
FT   VARIANT         897
FT                   /note="Y -> S (in VMCM; also found in a patient with
FT                   solitary sporadic venous malformations; increased
FT                   ligand-independent autophosphorylation and kinase
FT                   activation; dbSNP:rs80338909)"
FT                   /evidence="ECO:0000269|PubMed:10369874,
FT                   ECO:0000269|PubMed:19079259, ECO:0000269|PubMed:19888299"
FT                   /id="VAR_008716"
FT   VARIANT         914
FT                   /note="L -> F (found in patients with solitary and multiple
FT                   sporadic venous malformations; increased ligand-independent
FT                   autophosphorylation; novel location at endoplasmic
FT                   reticulum and Golgi apparatus; partially retained at
FT                   endoplasmic reticulum and Golgi apparatus)"
FT                   /evidence="ECO:0000269|PubMed:19079259"
FT                   /id="VAR_078051"
FT   VARIANT         915
FT                   /note="R -> C (found in a patient with solitary sporadic
FT                   venous malformations; increased ligand-independent
FT                   autophosphorylation)"
FT                   /evidence="ECO:0000269|PubMed:19079259"
FT                   /id="VAR_078052"
FT   VARIANT         915
FT                   /note="R -> H (in VMCM; strongly increased
FT                   ligand-independent autophosphorylation and kinase
FT                   activation; dbSNP:rs387906745)"
FT                   /evidence="ECO:0000269|PubMed:19888299"
FT                   /id="VAR_066607"
FT   VARIANT         915
FT                   /note="R -> L (found in a patient with multiple sporadic
FT                   venous malformations; increased ligand-independent
FT                   autophosphorylation; the autophosphorylation increases when
FT                   associated with Phe-897)"
FT                   /evidence="ECO:0000269|PubMed:19079259"
FT                   /id="VAR_078053"
FT   VARIANT         917
FT                   /note="S -> I (found in a patient with solitary sporadic
FT                   venous malformations; increased ligand-independent
FT                   autophosphorylation)"
FT                   /evidence="ECO:0000269|PubMed:19079259"
FT                   /id="VAR_078054"
FT   VARIANT         918
FT                   /note="R -> C (in VMCM; strongly increased
FT                   ligand-independent autophosphorylation and kinase
FT                   activation)"
FT                   /evidence="ECO:0000269|PubMed:19888299"
FT                   /id="VAR_066608"
FT   VARIANT         919
FT                   /note="V -> L (in VMCM; increased ligand-independent
FT                   autophosphorylation and kinase activation)"
FT                   /evidence="ECO:0000269|PubMed:19888299"
FT                   /id="VAR_066609"
FT   VARIANT         925
FT                   /note="A -> S (in VMCM; increased ligand-independent
FT                   autophosphorylation and kinase activation)"
FT                   /evidence="ECO:0000269|PubMed:19888299"
FT                   /id="VAR_066610"
FT   VARIANT         1100
FT                   /note="K -> N (in VMCM; strongly increased
FT                   ligand-independent autophosphorylation and kinase
FT                   activation)"
FT                   /evidence="ECO:0000269|PubMed:19888299"
FT                   /id="VAR_066611"
FT   VARIANT         1124
FT                   /note="A -> V (in a renal clear cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041862"
FT   MUTAGEN         224
FT                   /note="C->S: Reduces protein abundance."
FT                   /evidence="ECO:0000269|PubMed:27270174"
FT   MUTAGEN         855
FT                   /note="K->R: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:12609966,
FT                   ECO:0000269|PubMed:15851516"
FT   MUTAGEN         1102
FT                   /note="Y->F: Abolishes interaction with SHC1."
FT                   /evidence="ECO:0000269|PubMed:14665640"
FT   CONFLICT        536
FT                   /note="F -> L (in Ref. 2; BAG58094)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        695
FT                   /note="T -> I (in Ref. 1; AAA61139)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        939..940
FT                   /note="QQ -> HH (in Ref. 5; AAH35514)"
FT                   /evidence="ECO:0000305"
FT   STRAND          26..29
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          33..35
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          40..46
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          56..59
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   TURN            61..63
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          64..66
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          74..76
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          80..88
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          98..106
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          109..119
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          123..125
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          127..133
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          139..145
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          153..157
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          160..165
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   HELIX           167..169
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          172..178
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   HELIX           183..185
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          187..193
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   HELIX           198..200
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          202..208
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          215..217
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   TURN            235..237
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          246..248
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          259..261
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   TURN            271..276
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          279..281
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   TURN            282..285
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          286..288
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   HELIX           296..298
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          322..324
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   TURN            325..327
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          328..330
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          361..366
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          369..373
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   HELIX           380..382
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          383..386
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          396..400
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          405..408
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          411..414
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   HELIX           416..418
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          420..428
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          431..439
FT                   /evidence="ECO:0007829|PDB:2GY5"
FT   STRAND          446..449
FT                   /evidence="ECO:0007829|PDB:5UTK"
FT   STRAND          452..456
FT                   /evidence="ECO:0007829|PDB:5UTK"
FT   STRAND          461..464
FT                   /evidence="ECO:0007829|PDB:5UTK"
FT   STRAND          469..472
FT                   /evidence="ECO:0007829|PDB:5UTK"
FT   STRAND          476..485
FT                   /evidence="ECO:0007829|PDB:5UTK"
FT   STRAND          493..504
FT                   /evidence="ECO:0007829|PDB:5UTK"
FT   STRAND          512..521
FT                   /evidence="ECO:0007829|PDB:5UTK"
FT   STRAND          534..537
FT                   /evidence="ECO:0007829|PDB:5UTK"
FT   STRAND          550..555
FT                   /evidence="ECO:0007829|PDB:7E72"
FT   STRAND          558..562
FT                   /evidence="ECO:0007829|PDB:7E72"
FT   STRAND          569..572
FT                   /evidence="ECO:0007829|PDB:5MYA"
FT   STRAND          575..585
FT                   /evidence="ECO:0007829|PDB:7E72"
FT   STRAND          588..594
FT                   /evidence="ECO:0007829|PDB:7E72"
FT   STRAND          598..602
FT                   /evidence="ECO:0007829|PDB:7E72"
FT   STRAND          610..621
FT                   /evidence="ECO:0007829|PDB:7E72"
FT   STRAND          629..632
FT                   /evidence="ECO:0007829|PDB:7E72"
FT   STRAND          643..648
FT                   /evidence="ECO:0007829|PDB:7E72"
FT   STRAND          655..660
FT                   /evidence="ECO:0007829|PDB:7E72"
FT   STRAND          663..665
FT                   /evidence="ECO:0007829|PDB:7E72"
FT   STRAND          669..677
FT                   /evidence="ECO:0007829|PDB:7E72"
FT   STRAND          683..689
FT                   /evidence="ECO:0007829|PDB:7E72"
FT   STRAND          696..699
FT                   /evidence="ECO:0007829|PDB:7E72"
FT   STRAND          707..715
FT                   /evidence="ECO:0007829|PDB:7E72"
FT   STRAND          727..730
FT                   /evidence="ECO:0007829|PDB:7E72"
FT   STRAND          816..818
FT                   /evidence="ECO:0007829|PDB:1FVR"
FT   HELIX           821..823
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   STRAND          824..833
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   STRAND          836..845
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   STRAND          848..857
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   HELIX           864..866
FT                   /evidence="ECO:0007829|PDB:2P4I"
FT   HELIX           872..879
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   STRAND          888..894
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   STRAND          897..903
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   HELIX           910..916
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   HELIX           919..922
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   HELIX           924..929
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   STRAND          932..936
FT                   /evidence="ECO:0007829|PDB:2OO8"
FT   HELIX           938..957
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   HELIX           967..969
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   STRAND          970..972
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   HELIX           974..976
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   STRAND          978..980
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   HELIX           985..987
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   HELIX           1000..1004
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   HELIX           1007..1012
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   HELIX           1017..1032
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   TURN            1038..1041
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   HELIX           1044..1050
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   HELIX           1051..1053
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   HELIX           1065..1074
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   HELIX           1079..1081
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   HELIX           1085..1097
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   STRAND          1098..1100
FT                   /evidence="ECO:0007829|PDB:6MWE"
FT   HELIX           1118..1120
FT                   /evidence="ECO:0007829|PDB:6MWE"
SQ   SEQUENCE   1124 AA;  125830 MW;  E739DEC3E4FEB124 CRC64;
     MDSLASLVLC GVSLLLSGTV EGAMDLILIN SLPLVSDAET SLTCIASGWR PHEPITIGRD
     FEALMNQHQD PLEVTQDVTR EWAKKVVWKR EKASKINGAY FCEGRVRGEA IRIRTMKMRQ
     QASFLPATLT MTVDKGDNVN ISFKKVLIKE EDAVIYKNGS FIHSVPRHEV PDILEVHLPH
     AQPQDAGVYS ARYIGGNLFT SAFTRLIVRR CEAQKWGPEC NHLCTACMNN GVCHEDTGEC
     ICPPGFMGRT CEKACELHTF GRTCKERCSG QEGCKSYVFC LPDPYGCSCA TGWKGLQCNE
     ACHPGFYGPD CKLRCSCNNG EMCDRFQGCL CSPGWQGLQC EREGIQRMTP KIVDLPDHIE
     VNSGKFNPIC KASGWPLPTN EEMTLVKPDG TVLHPKDFNH TDHFSVAIFT IHRILPPDSG
     VWVCSVNTVA GMVEKPFNIS VKVLPKPLNA PNVIDTGHNF AVINISSEPY FGDGPIKSKK
     LLYKPVNHYE AWQHIQVTNE IVTLNYLEPR TEYELCVQLV RRGEGGEGHP GPVRRFTTAS
     IGLPPPRGLN LLPKSQTTLN LTWQPIFPSS EDDFYVEVER RSVQKSDQQN IKVPGNLTSV
     LLNNLHPREQ YVVRARVNTK AQGEWSEDLT AWTLSDILPP QPENIKISNI THSSAVISWT
     ILDGYSISSI TIRYKVQGKN EDQHVDVKIK NATITQYQLK GLEPETAYQV DIFAENNIGS
     SNPAFSHELV TLPESQAPAD LGGGKMLLIA ILGSAGMTCL TVLLAFLIIL QLKRANVQRR
     MAQAFQNVRE EPAVQFNSGT LALNRKVKNN PDPTIYPVLD WNDIKFQDVI GEGNFGQVLK
     ARIKKDGLRM DAAIKRMKEY ASKDDHRDFA GELEVLCKLG HHPNIINLLG ACEHRGYLYL
     AIEYAPHGNL LDFLRKSRVL ETDPAFAIAN STASTLSSQQ LLHFAADVAR GMDYLSQKQF
     IHRDLAARNI LVGENYVAKI ADFGLSRGQE VYVKKTMGRL PVRWMAIESL NYSVYTTNSD
     VWSYGVLLWE IVSLGGTPYC GMTCAELYEK LPQGYRLEKP LNCDDEVYDL MRQCWREKPY
     ERPSFAQILV SLNRMLEERK TYVNTTLYEK FTYAGIDCSA EEAA
//
